Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Da Yuan Yin
- Development stage
- Preclinical
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Administration
- Oral
01
Overview
Da Yuan Yin (DYY) is a classical Traditional Chinese Medicine (TCM) decoction, originally described in the 17th-century text *Wen Yi Lun* (Treatise on Pestilence) for the treatment of infectious diseases. Modern pharmacological research identifies DYY as a potential therapeutic for sepsis, demonstrating significant anti-inflammatory and intestinal protective effects. In preclinical models, DYY has been shown to alleviate sepsis-induced intestinal injury by suppressing the production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, and by promoting the expression of intestinal tight junction proteins like claudin-1, occludin, and ZO-1. Furthermore, DYY modulates the gut microbiota, specifically promoting the growth of beneficial bacteria such as Lactobacillales, which leads to increased levels of protective short-chain fatty acids (SCFAs) and reduced β-glucuronidase activity. These combined actions help maintain intestinal homeostasis and mitigate systemic organ dysfunction during sepsis.
- Other names
- DayuanyinDayuan Decoction
02
Targets
CLDN1 (Tight junction protein claudin-1)IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)OCLN (Occludin)TNFA (Tumor necrosis factor alpha (soluble))TJP1 (Tight junction protein 1 (ZO-1))
Beyond the preview
Go deeper on Da Yuan Yin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Da Yuan Yin.